Dr. Myles Wolf is a Professor of Medicine and Chief of the Division of Nephrology at the Duke University School of Medicine. Dr. Wolf was awarded the Charles Johnson, MD, Chair of Medicine in 2018.
Dr. Wolf is internationally recognized as a leading clinical nephrologist and physician-scientist in the fields of disordered mineral metabolism and cardiovascular disease in patients with chronic kidney disease (CKD). Dr. Wolf’s groundbreaking research of the bone-derived phosphate-regulating hormone, fibroblast growth factor 23 (FGF23), was instrumental in advancing new paradigms and identifying new therapeutic targets at the nexus of kidney and cardiovascular diseases. His research on FGF23 helped to redefine the pathophysiology of disordered mineral metabolism in CKD and has been adopted in textbooks and board exams. His epidemiological research identified elevated levels of FGF23 as a novel predictor of cardiovascular events and death, and his basic research suggested novel molecular mechanisms underlying these relationships.
Dr. Wolf earned his B.A. in biology from the Johns Hopkins University, his M.D. from the State University of New York, Downstate, and his Master of Medical Sciences Degree in Clinical and Physiological Investigation from Harvard Medical School. He completed his internship and residency, and a fellowship in nephrology, at the Massachusetts General Hospital.
Before joining Duke in 2016, he was on the faculty of Harvard Medical School; the University of Miami Miller School of Medicine, where he served as assistant dean for translational and clinical research and as chief of the Division of Nephrology and Hypertension; and the Northwestern University Feinberg School of Medicine, where he served as founding Director of the Center for Translational Metabolism and Health, and Director of the Department of Medicine’s Physician Scientist Training Program.